Insights

345 Park Avenue South

Xchange Challenge

All floors are lab-ready and cabled for digital health.

Community

Residents

Leadership

Staff

Neighborhood

Be part of *Cure.*

Orange

Where scientists, entrepreneurs and visionaries converge.

Campus

Ecosystem

Event Spaces

Gallery

Networking hub

Space Availability

A place to *Succeed.*

Green

Joe Wilson How Life Sciences Companies Use AI to Target Investors Mega Menu Image 

Critical Discussions Advancing Healthcare

Events

Event Inquiry

Past Events

Speakers

Tuesday Talks

Cure *Events.*

Magenta

Cure Clips

Tuesday Talks Series

Cure *Tuesday Talks*

Award Finalists to be announced soon!

Partnerships and Sponsorships

Women in Science

XSeed Award

Connect with *Opportunity.*

Blue

Network

Cure Insights Article A Bionic Pancreas that will Help Parents Sleep More Peacefully image for Cure Insights Mega Menu.  Image credit Cottonbro Studio.

A Bionic Pancreas that will Help Parents Sleep More Peacefully

In-depth *Insights.*

About

Contact us

Stay updated on platform news and potential beta tests.

Regular

Joseph La Barge, JD, is CEO and serves on the Board of Managers of Apertura Gene Therapy.

Previously, he was an executive at Spark Therapeutics, Inc., serving as Chief Business Officer from 2019 to 2021 and as Chief Legal Officer from 2013 to 2019. In these roles, he oversaw many areas of the company’s growth, including business development, patient advocacy, quality assurance, legal affairs, compliance, finance, public policy, and global pricing and reimbursement, growing the company to 830 employees over eight years. He led the negotiation of Spark’s acquisition by Roche, raised more than $1 billion in capital from private and public financings, and oversaw the in-license of numerous product candidates and platform technologies.

La Barge also managed the acquisition and construction of Spark’s initial 180,000 square feet of office and laboratory space, including GMP suites, to manufacture the global supply of Luxturna.

CEO, Apertura